drugset / Trial / NCT01096004

Study to Evaluate Methods That Assess the Effect of AZD4017 in Adipose Tissue

NCT01096004

Phase 1 Completed 15 enrolled AstraZeneca
RandomizedParallel-groupSingle-blind

Summary

The primary purpose of this study is to investigate different methods to evaluate the effect of AZD4017 in adipose tissue after single and multiple doses of AZD4017 in abdominally obese but otherwise healthy subjects.

Timeline

Start
2010-03
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD4017 Small molecule 1200 mg Oral

Indications